FDA approves first COVID treatment pill Paxlovid by Pfizer

FDA approves first COVID treatment pill

This week, the U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) of the first antiviral pill to treat COVID-19 at home. Called Paxlovid, it is intended for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older).

Paxlovid is made by Pfizer. It's taken twice a day for five days in combination with a second medicine called ritonavir, a generic antiviral. It is the first treatment for COVID-19 that is in the form of a pill that is taken orally.

Who can use Paxlovid?

The current guidelines for use of Paxlovid are:

  • Adults and children who are 12 years of age and older weighing at least 88 pounds (40 kg)
  • With a confirmed COVID-19 infection
  • Within five days of symptoms onset
  • Who are at high risk for progression to severe COVID-19, including hospitalization or death, irrespective of vaccination status (for example: Immune-compromised, cancer, multiple advanced medical comorbidities, >60 years old)

Availability at ARC

As of now, we have been informed that it will take a few days to a couple of weeks before Paxlovid is shipped by the manufacturer and before it will become available for prescribing. ARC doctors will begin prescribing Paxlovid as soon as it becomes available in our community.

In the meantime…

Please continue taking all precautions against COVID-19, including vaccination and booster shot, masking when inside and when in crowded outdoor situations, hand hygiene, and social distancing.

If you need a COVID-19 vaccine or booster, they are available at ARC by appointment. Book a COVID vaccine or booster appointment online.

If you need a COVID-19 test, they are available at ARC by appointment. Book a COVID test online.

Current treatment. Monoclonal antibody treatment is currently available in the Austin area. If you are at elevated risk of severe COVID-19 and/or hospitalization, ask your physician about this treatment.

Still have questions? Visit our COVID-19 FAQ page for answers.


Tags: COVID-19, paxlovid

More on this Topic

FDA and CDC authorize COVID-19 booster for omicron variant

ARC is awaiting our Omicron Booster vaccine shipment. Schedules will be open at MyChartARC.com as soon as we receive vaccine. Read more.

COVID-19 vax scheduling open for children 6 mo-5 yrs

The CDC and the FDA have approved the age-appropriate Pfizer BioNTech and Moderna vaccines for infants and young children and both vaccines are available by appointment at all ARC primary care locationsHere’s how to book

ARC enrolling for COVID-19 variants vaccine trial

ARC is currently enrolling participants in a study testing an “updated” vaccine targeting specific variants. Learn more.

What have we learned in two years of COVID-19?

Anas Daghestani, MD, ARC CEO, and Amy B. Siegel, MD, ARC Internal Medicine and ARC Clinical Researcher, share their thoughts and lessons from the last two years of the pandemic in this recent article.

Keeping you up to date on the COVID-19 kids vax

Elizabeth C. Knapp, MD, Pediatrics at ARC Far West, sat down to talk to Spectrum News about the latest news on the COVID-19 vaccine for kids ages 5-11 years old. Hear what she has to say about the efficacy and safety of this shot for children.